Adoptive Immunotherapy for Renal Adenocarcinoma: Use of Oxidizing Mitogen-Treated Mononuclear Leukocytes and Continuous Infusion of Interleukin-2

Infusion of recombinant interleukin-2 (rIL-2) in combination with autologous peripheral blood mononuclear cells (PBM) treated with rIL-2 can induce regression of tumors in some patients with metastatic renal adenocarcinoma or melanoma. Initial response rates in metastatic renal adenocarcinoma of 16%–33% were reported [1, 5].